Company Overview and News
20h seekingalpha - 4
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
CAT UVVZP RGS SIRI TJX SNCR AEP NOK CAG FSLR KIM PFSI SNAP RUBI ABX MO MMM MRCY GILD MCFT ETR ABRW BABA GSHD DVMT JNJ VZ MSFT LMT QTT PRNB SCG TM DOCU AMD QNST BAC SMAR OKE INTC BIDU PRFT CREE UN UVV LLY GSK JPM FVCB NUAN WRK ARRY AX PCSB FCX ZPTAF CFIN AMZN CIWV CDAY TWTR OMC CELG GSK AGNC LASR MAC YI BAC AAL QURE NBEV AUDVF CTSH CMG GOOGL BA PFE KRNY DRE PF SGY COP SPVEF GM ALZH ORCL MCD BMY F ABX CMCSA TECH MSTR SPVVF CFG V LAIX T MRK SNE
I am not going to tell you that the market dropped like a rock last week or that there are "stocks on sale" due to the latest drop. You have already been submerged by those kinds of stories, right? In fact, I want to talk about companies that have been deeply suffering for a while now. You may think the TSX is on sale right now, but in fact, it is only down five percent. Would you rush into the store if Boxing Day could get you five percent off of your next TV?
BCE RCIAF RCI VZ CPXGF TU
WASHINGTON (Reuters) - Five industry groups representing major internet providers and cable companies filed suit on Thursday seeking to block a Vermont law barring companies that do not abide by net neutrality rules from receiving state contracts.
FB CCV.CL GOOGL CCV CMCSA VZ CCZ GOOG CMCSK VZA
Four industry groups representing major internet providers and cable companies filed suit on Thursday seeking to block Vermont's state law barring companies that do not abide by net neutrality rules from receiving state contracts.
FB CCV.CL GOOGL CCV CMCSA VZ CCZ GOOG CMCSK VZA
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"[email protected],"!O8FH-/#PO3&EN96%R:7IE9" [email protected],S,S M-S,O3R Q,2]%(#(X,S [email protected],B]4(#,S,#7!E+UA2968O5ULQ(#(@,5T^/G-T('$UUX&)D:&&2 E#(Q,_QEW_P<(, "[email protected][email protected] M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HQ.2 P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X,R],96YG [email protected]@-S O4R T.#X^
Verizon Communications (VZ - Free Report) closed at $53.96 in the latest trading session, marking a +0.48% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.03%. At the same time, the Dow lost 0.36%, and the tech-heavy Nasdaq lost 0.04%.
OLBK VZ RLI VZA
Dividend growth stocks have taken it on the chin in October. That’s especially true of S&P 500 tech sector stocks. Only consumer discretionary and materials stocks have done worse over the same period.
HBANN HBANO F HBANP CIB MC HMC HBAN APAM LULU VZ GM
Last week, just days after flirting with the 27,000 threshold and setting new record highs, the Dow Jones Industrial Average plunged on worries over the impact rising long-term interest rates would have on the economy amid the Federal Reserve’s ongoing tightening cycle. This week, after the harrowing selloff, U.S. equities found respite thanks to these Dow Jones stocks.
DB CVX VZ KO BA INTC MCD DIS
Wall Street expects a year-over-year increase in earnings on higher revenues when Verizon Communications (VZ - Free Report) reports results for the quarter ended September 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
WNEB VZ VZA
2018-10-16 thestar - 1
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
AAPL VZ MSFT NVDA QCOM VZA
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to VZ / Verizon Communications, Inc. on message board site Silicon Investor.
|Verizon Communications (VZ)||Verizon Communications (VZ)||Verizon Communications (VZ)||INVZ Undiscoverd internet gem!||INVZ Undiscoverd internet gem!||INVZ Undiscoverd internet gem!|
as of ET